Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Express Scripts
Harvard Business School
AstraZeneca
Baxter

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,887,845

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,887,845 protect, and when does it expire?

Patent 7,887,845 protects INTELENCE and is included in one NDA.

Protection for INTELENCE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighty-five patent family members in thirty-six countries.

Summary for Patent: 7,887,845
Title:Antiviral compositions
Abstract:The present invention is concerned with pharmaceutical compositions of antiviral compounds which can be administered to a mammal, in particular a human, suffering from a viral infection. These compositions comprise particles obtainable by melt-extruding a mixture comprising one or more antiviral compounds and one or more appropriate water-soluble polymers and subsequently milling said melt-extruded mixture.
Inventor(s): Verreck; Geert (Malle, BE), Baert; Lieven (Brugge 2, BE)
Assignee: Janssen Pharmaceutica NV (BE)
Application Number:11/347,071
Patent Claim Types:
see list of patent claims
Compound; Formulation; Composition; Dosage form; Process;

Drugs Protected by US Patent 7,887,845

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-003 Mar 26, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-001 Jan 18, 2008 RX Yes No   Start Trial   Start Trial Y   Start Trial
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-002 Dec 22, 2010 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,887,845

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
99203128Sep 24, 1999

International Family Members for US Patent 7,887,845

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1636   Start Trial
African Regional IP Organization (ARIPO) 1639   Start Trial
Argentina 021137   Start Trial
Austria 315031   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKinsey
Express Scripts
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.